Who are sirolimus, tacrolimus, mycophenolate mofetil's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sirolimus-tacrolimus-mycophenolate-mofetil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

sirolimus, tacrolimus, mycophenolate mofetil — Competitive Intelligence Brief

sirolimus, tacrolimus, mycophenolate mofetil (sirolimus, tacrolimus, mycophenolate mofetil) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive agent combination. Area: Immunology.

marketed Immunosuppressive agent combination mTOR, calcineurin, IMPDH Immunology Small molecule Live · refreshed every 30 min

Target snapshot

sirolimus, tacrolimus, mycophenolate mofetil (sirolimus, tacrolimus, mycophenolate mofetil) — National Taiwan University Hospital. This triple immunosuppressive regimen inhibits T-cell proliferation and activation through distinct mechanisms to prevent organ rejection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
sirolimus, tacrolimus, mycophenolate mofetil TARGET	sirolimus, tacrolimus, mycophenolate mofetil	National Taiwan University Hospital	marketed	Immunosuppressive agent combination	mTOR, calcineurin, IMPDH

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive agent combination class)

National Taiwan University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). sirolimus, tacrolimus, mycophenolate mofetil — Competitive Intelligence Brief. https://druglandscape.com/ci/sirolimus-tacrolimus-mycophenolate-mofetil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab